Immune-based therapies for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinato, David J., Guerra, Nadia, Fessas, Petros, Murphy, Ravindhi, Mineo, Takashi, Mauri, Francesco A., Mukherjee, Sujit K., Thursz, Mark, Wong, Ching Ngar, Sharma, Rohini, Rimassa, Lorenza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190571/
https://www.ncbi.nlm.nih.gov/pubmed/32157213
http://dx.doi.org/10.1038/s41388-020-1249-9
_version_ 1783527708726132736
author Pinato, David J.
Guerra, Nadia
Fessas, Petros
Murphy, Ravindhi
Mineo, Takashi
Mauri, Francesco A.
Mukherjee, Sujit K.
Thursz, Mark
Wong, Ching Ngar
Sharma, Rohini
Rimassa, Lorenza
author_facet Pinato, David J.
Guerra, Nadia
Fessas, Petros
Murphy, Ravindhi
Mineo, Takashi
Mauri, Francesco A.
Mukherjee, Sujit K.
Thursz, Mark
Wong, Ching Ngar
Sharma, Rohini
Rimassa, Lorenza
author_sort Pinato, David J.
collection PubMed
description Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.
format Online
Article
Text
id pubmed-7190571
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71905712020-05-04 Immune-based therapies for hepatocellular carcinoma Pinato, David J. Guerra, Nadia Fessas, Petros Murphy, Ravindhi Mineo, Takashi Mauri, Francesco A. Mukherjee, Sujit K. Thursz, Mark Wong, Ching Ngar Sharma, Rohini Rimassa, Lorenza Oncogene Review Article Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area. Nature Publishing Group UK 2020-03-10 2020 /pmc/articles/PMC7190571/ /pubmed/32157213 http://dx.doi.org/10.1038/s41388-020-1249-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Pinato, David J.
Guerra, Nadia
Fessas, Petros
Murphy, Ravindhi
Mineo, Takashi
Mauri, Francesco A.
Mukherjee, Sujit K.
Thursz, Mark
Wong, Ching Ngar
Sharma, Rohini
Rimassa, Lorenza
Immune-based therapies for hepatocellular carcinoma
title Immune-based therapies for hepatocellular carcinoma
title_full Immune-based therapies for hepatocellular carcinoma
title_fullStr Immune-based therapies for hepatocellular carcinoma
title_full_unstemmed Immune-based therapies for hepatocellular carcinoma
title_short Immune-based therapies for hepatocellular carcinoma
title_sort immune-based therapies for hepatocellular carcinoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190571/
https://www.ncbi.nlm.nih.gov/pubmed/32157213
http://dx.doi.org/10.1038/s41388-020-1249-9
work_keys_str_mv AT pinatodavidj immunebasedtherapiesforhepatocellularcarcinoma
AT guerranadia immunebasedtherapiesforhepatocellularcarcinoma
AT fessaspetros immunebasedtherapiesforhepatocellularcarcinoma
AT murphyravindhi immunebasedtherapiesforhepatocellularcarcinoma
AT mineotakashi immunebasedtherapiesforhepatocellularcarcinoma
AT maurifrancescoa immunebasedtherapiesforhepatocellularcarcinoma
AT mukherjeesujitk immunebasedtherapiesforhepatocellularcarcinoma
AT thurszmark immunebasedtherapiesforhepatocellularcarcinoma
AT wongchingngar immunebasedtherapiesforhepatocellularcarcinoma
AT sharmarohini immunebasedtherapiesforhepatocellularcarcinoma
AT rimassalorenza immunebasedtherapiesforhepatocellularcarcinoma

Ejemplares similares